Dougherty & Co Equities Analysts Decrease Earnings Estimates for IntriCon Co. (NASDAQ:IIN)

IntriCon Co. (NASDAQ:IIN) – Equities researchers at Dougherty & Co reduced their FY2017 earnings per share (EPS) estimates for IntriCon in a note issued to investors on Tuesday, Zacks Investment Research reports. Dougherty & Co analyst R. Ryan now forecasts that the technology company will post earnings of $0.24 per share for the year, down from their previous estimate of $0.26. Dougherty & Co also issued estimates for IntriCon’s FY2018 earnings at $0.60 EPS.

Several other equities research analysts also recently weighed in on the company. Zacks Investment Research raised IntriCon from a “hold” rating to a “strong-buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, January 3rd. TheStreet raised IntriCon from a “c” rating to a “b-” rating in a research report on Wednesday, November 8th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $17.00.

Shares of IntriCon (NASDAQ:IIN) traded up $0.75 on Wednesday, reaching $21.75. The company’s stock had a trading volume of 72,533 shares, compared to its average volume of 70,880. The firm has a market cap of $149.40, a P/E ratio of 103.57, a P/E/G ratio of 1.75 and a beta of 0.40. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.45 and a quick ratio of 0.54. IntriCon has a 12 month low of $6.05 and a 12 month high of $22.30.

Several hedge funds have recently bought and sold shares of the company. Pacific Alternative Asset Management Company LLC lifted its stake in IntriCon by 73.4% in the 2nd quarter. Pacific Alternative Asset Management Company LLC now owns 292,853 shares of the technology company’s stock valued at $2,394,000 after buying an additional 123,942 shares in the last quarter. EAM Investors LLC purchased a new position in IntriCon in the 3rd quarter valued at about $588,000. Algert Global LLC purchased a new position in IntriCon in the 3rd quarter valued at about $396,000. Essex Investment Management Co. LLC purchased a new position in IntriCon in the 3rd quarter valued at about $267,000. Finally, Heartland Advisors Inc. lifted its stake in IntriCon by 0.6% in the 2nd quarter. Heartland Advisors Inc. now owns 809,499 shares of the technology company’s stock valued at $6,618,000 after buying an additional 4,622 shares in the last quarter. 33.89% of the stock is currently owned by institutional investors and hedge funds.

In other news, VP Michael Geraci sold 2,737 shares of the stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $17.60, for a total transaction of $48,171.20. Following the sale, the vice president now directly owns 22,011 shares of the company’s stock, valued at approximately $387,393.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 21.40% of the company’s stock.

WARNING: “Dougherty & Co Equities Analysts Decrease Earnings Estimates for IntriCon Co. (NASDAQ:IIN)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/dougherty-co-equities-analysts-decrease-earnings-estimates-for-intricon-co-iin.html.

About IntriCon

IntriCon Corporation is engaged in designing, developing, engineering, manufacturing and distributing body-worn devices. The Company operates through body-worn device segment. The Company serves the body-worn device market by designing, developing, engineering and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies, complete assemblies and software solutions, primarily for the value hearing health market, the medical bio-telemetry market and the professional audio communication market.

Get a free copy of the Zacks research report on IntriCon (IIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply